drug

Thailand issues license to manufacture generic version of Efavirenz; snubs Merck AIDS drug monopoly

Monday, December 04, 2006 by: Jessica Fraser
Tags: AIDS, intellectual property, drug patents

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
Malaysia Airlines Flight 370 now clearly a government cover-up: All evidence contradicts official story
White House admits staging fake vaccination operation to gather DNA from the public
10 other companies that use the same Subway yoga mat chemical in their buns
High-dose vitamin C injections shown to annihilate cancer
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Global warming data FAKED by government to fit climate change fictions
U.S. treating meat with ammonia, bleach and antibiotics to kill the '24-hour sickness'
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ben and Jerry's switches to non-GMO, Fair Trade ice cream ingredients
Battle for humanity nearly lost: global food supply deliberately engineered to end life, not nourish it
Diet soda, aspartame linked to premature deaths in women
Cannabis kicks Lyme disease to the curb
Elliot Rodger, like nearly all young killers, was taking psychiatric drugs (Xanax)
Harvard research links fluoridated water to ADHD, mental disorders
Right to farm being stripped from Americans: Michigan to criminalize small family farms with chickens, goats, honey bees and more
Delicious
(NaturalNews) Thailand announced last week that because of rising prices of foreign-made HIV/AIDS drugs, it would issue a five-year license to manufacture an inexpensive generic version of Merck & Co.'s Efavirenz drug.

Though Merck -- which holds the patent on Efavirenz -- criticized the military Thai government's decision to make its own cheaper version of the anti-retroviral drug, health advocates and AIDS activists commended the Health Ministry.

"This is both a brave and a progressive step by the Royal Thai Government to place the interests of people living with HIV in Thailand front and center," said UNAIDS country coordinator Patrick Brenny.

The Thai government -- headed by the military after a September coup to oust former prime minister Thaksin Shinawatra -- declared a "national emergency" under World Trade Organization rules that allow governments to issue compulsory licenses to manufacture patented drugs without consent from the patent holder. Merck will receive a royalty of 0.5 percent on sales of its generic version of the drug, which will cost half what Merck charged for Efavirenz.

Thailand's national drug program, which treats 82,000 of the 580,000 HIV/AIDS patients in the country, has gained international recognition for its efficacy. However, as AIDS patients live longer and foreign drug companies boost prices, the government has struggled with costs.

Thawat Suntrajarn, head of the Health Ministry's Department of Disease Control, said foreign companies' prices are "very high, making it a big hurdle for patients to access [HIV/AIDS drugs] and the government cannot afford them. In the long run [patients] need this anti-retroviral drug to live a normal life like others."

Consumer health advocate Mike Adams, a vocal critic of intellectual property rights for pharmaceuticals, said more and more countries are beginning to question the patent protection pharmaceutical companies are granted for chemical compounds.

"When it comes to AIDS and public health, most people in the world believe that drugs should be open source and available to the public at non-monopolistic prices," Adams said. "But drug companies want to soak the population for as much money as they can, without consideration for whether people have AIDS, cancer or other diseases.

"They want to enforce profiteering prices on everyone, and they use the protection of intellectual property patents to get away with it," he said.

Merck claims it makes no profits off Efavirenz in Thailand, and that the Thai government did not contact the company to attempt to resolve the cost problems before issuing the generic production license.

According to a World Bank study of the Thai drug program, the government took a risk in overriding Merck's patent, as the decision could result in trade repercussions. However, supporters of the generic manufacturing license say the move could bolster Thailand's ability to negotiate lower prices with other drug firms.

###

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.